Navigation Links
STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
Date:1/14/2010

Area and Severity Index (PASI 75) at week 12, the primary endpoint, compared with 57 percent of patients receiving subcutaneous injections of 50 mg etanercept twice per week for 12 weeks (P = 0.01 for STELARA 45 mg; P < 0.001 for STELARA 90 mg, each compared with etanercept).  Onset of clinical response appeared more rapidly among STELARA-treated patients, with higher numbers of patients achieving PASI 75 by week 8 compared with patients receiving etanercept.  

Investigators also reported that a greater proportion of patients receiving STELARA achieved a marked improvement in psoriasis as assessed by PASI 90 response, or nearly complete clearance of psoriasis.  At week 12, 36 percent of patients receiving STELARA 45 mg and 45 percent of patients receiving STELARA 90 mg achieved PASI 90 compared with 23 percent of patients receiving etanercept (P < 0.001 for each comparison versus etanercept).  Moreover, a greater proportion of patients in both the STELARA 45 mg and 90 mg treatment groups achieved a Physician Global Assessment (PGA) score of "cleared" or "minimal" (65 percent and 71 percent, respectively) compared with patients in the etanercept treatment group (49 percent) (P < 0.001 for each comparison versus etanercept).

Patients who had an inadequate response to etanercept, as measured by PGA score (classified as moderate, marked or severe psoriasis at week 12), received one injection of STELARA 90 mg at weeks 16 and 20.  At week 28, investigators reported that 49 and 23 percent of patients who failed to respond to etanercept and who crossed over to STELARA achieved PASI 75 and PASI 90, respectively.

In addition, patients classified as responders (having a PGA score of cleared, minimal or mild) at week 12 discontinued therapy until recurrence of psoriasis (PGA of moderate or greater).  In these patients, the median length of time to disease recurrence was l
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) today ... Science Firm of the Year by the Tech Council of ... the TCM,s 25 th Annual Tech Awards Celebration held ... Celebration recognizes the leaders and innovators in the technology and ... the surrounding regions. "We are deeply honored ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... May 23, 2013 Neurocrine Biosciences, Inc. (Nasdaq: ... , President and Chief Executive Officer of Neurocrine Biosciences, ... Annual dbAccess Health Care Conference in Boston.   ... 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time.  The ... Company,s website at http://www.neurocrine.com . If ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:5/23/2013)... is associated with poor outcomes in hospitalized patients, and ... is a common practice in hospitals. But the recent ... shows harms associated with the use of IIT, according ... Committee in a new evidence-based paper published today online ... , "Clinicians caring for hospitalized patients must keep the ...
(Date:5/23/2013)... 2013 Internationally recognized as one of ... for over 29 years, Coach Nick Saviano’s ... WTA players, Grand Slam winners, World #1’s; Junior Wimbledon, ... USTA National Junior Champions, 8 Foreign National Junior Champions ... Cup, Orange Bowl and Eddie Herr winners - and ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Whether working ... Operations Forces and law enforcement need an added layer ... Security Enhancer, Night VISER , is an effective ... motion sensing system to increase border and perimeter security. ... VISER have more than tripled over the past three ...
(Date:5/23/2013)... UNITED KINGDOM (PRWEB) May 24, 2013 ... by A.L. Hodkin, A.F. Huxley and B. Katz in ... to account for the role of sodium and potassium ... electrophysiological techniques and the data acquisition techniques have known ... Yves Pichon wants to give an account of ...
(Date:5/23/2013)... In his pulse-quickening novel, “The AIDS Covenant” (published by AuthorHouse), ... government?” , In the “The AIDS Covenant,” readers meet Dr. ... ’s Heathrow Airport. His American colleague, Alan Milner of BAYMED ... arrive at his Sierra Nevada ski-lodge. , ... the government’s report. When Alan learns that Owen was killed ...
Breaking Medicine News(10 mins):Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3Health News:New Book “The AIDS Covenant” by Roy Harris Delivers Intriguing, Captivating Story 2
... The National Commander of the Disabled American Veterans begins ... support for budget reform legislation to ensure sufficient, timely ... is urging them to reject a contentious proposal that ... conditions from the government,s side of the ledger to ...
... cranberriesand not the acidity of cranberry juice, as previously ... line the urinary tract, as documented in a report ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( ... www.liebertpub.com/jmf , Urinary tract infections (UTIs) burden ...
... March 9 Quest Diagnostics Incorporated (NYSE: ... information and services, announced that it is scheduled to ... on Tuesday, March 10, 2009. The Quest Diagnostics ... Time.During the conference, the company will reaffirm its 2009 ...
... Sport Beans and Nike Motivate College Students to Complete ... SpringNEW YORK, March 9 American Collegiate Intramural Sports ... corporate sponsors are joining together to launch ACIS Fitness ... college marketing platform is aimed at motivating the 2.7 ...
... Japanese scientists will arrive at the University of Houston ... that promises to deliver more comprehensive and accurate insights ... of current technologies. , In April, Mikio Kubota of ... join the research team at UH,s Biomedical Imaging Lab. ...
... President Obama signed an executive order ... stem cell research, overturning limits on federal funding for ... President & CEO of Americans United for Life responded, ... past. Millions of dollars have been spent on ...
Cached Medicine News:Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:New research reveals how cranberry products prevent urinary tract infections 2Health News:Quest Diagnostics to Speak at Barclays Capital Global Healthcare Conference 2Health News:ACIS Fitness Challenges Launch Across 200 Colleges Nationwide 2Health News:UH research team developing new noninvasive brain-mapping technology 2Health News:UH research team developing new noninvasive brain-mapping technology 3Health News:UH research team developing new noninvasive brain-mapping technology 4Health News:Americans United for Life: Obama Administration Stem Cell Policy an Anti-Life Waste of Tax Dollars 2
... tissue, mucous, and other body fluids -- ... as box joints and tubing -- while ... Original is strong enough for the toughest ... everyday. Prolong the life of your instruments ...
... MPD is the highly ... surgical instruments manually or with an ... enough to remove blood and organic ... cleaning. Use MPD to clean surgical ...
... Features you need for critical patients ... blood,pressures, a comprehensive calculations package and ... that you can transport with your ... frequently used functions which means ...
The ApexPro CH is operational within the WMTS. It offers operating performance, up to 240 WMTS channels, and up to 120 hours of battery life....
Medicine Products: